Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism

New England Journal of Medicine

Volumn 349, Issue 7, 2003, Pages 631-639

  Kearon, Clive ^a,b   Ginsberg, Jeffrey S ^a,b   Kovacs, Michael J ^c   Anderson, David R ^d   Wells, Philip ^e   Julian, Jim A ^a,b   MacKinnon, Betsy ^a,b   Weitz, Jeffrey I ^a,b   Crowther, Mark A ^a   Dolan, Sean ^f   Turpie, Alexander G ^a   Geerts, William ^g   Solymoss, Susan ^h   Van Nguyen, Paul ⁱ   Demers, Christine ^j   Kahn, Susan R ^h   Kassis, Jeannine ⁱ   Rodger, Marc ^e   Hambleton, Julie ^k   Gent, Michael ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON RESEARCH CENTRE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF NEW BRUNSWICK   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITÉ DE MONTRÉAL   (Canada)

^j UNIVERSITÉ LAVAL   (Canada)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HAZARD ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; THROMBOEMBOLISM; AGE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; FOLLOW UP; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RISK FACTOR; TREATMENT OUTCOME; VEIN THROMBOSIS;

AGE FACTORS; AGED; ANTICOAGULANTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN;

EID: 0042031415     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa035422     Document Type: Article

References (11)

1. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:Suppl I:I-2-I-30.
2. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-7. [Erratum, N Engl J Med 1999;341:298.]
3. Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-8.
4. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
5. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
6. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:Suppl:8S-21S.
7. Kaplan EL, Meler P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
8. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
9. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-34.
10. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999;81:684-9.
11. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-9.